Teladoc Health stock holds after a $606.9 million quarter
Published on 08/31/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teladoc Health, Inc. (ISIN US87918A1051) is being judged against a second-quarter revenue base of $606.9 million and adjusted EPS of -$0.21, while Q3 2026 guidance calls for EPS between -$0.30 and -$0.20. The current analyst view also points to a consensus target of $7.54 and a Hold rating, with one recent brokerage note cutting its target from $11.00 to $7.50.
Quarterly numbers set the tone
Revenue of $606.9 million in the quarter cited by MarketBeat was down 4 percent year over year, and the same source said the company posted an adjusted loss of $0.21 a share versus an expected loss of $0.25. That makes the quarter better than the earnings estimate, but softer on sales.
The same report said Teladoc Health's full-year 2026 guidance stands at EPS between -$1.00 and -$0.75, while analysts surveyed there expect -$0.89 per share for the year. The gap between the company range and the consensus estimate is narrow, and that keeps guidance the key number for investors.
Consensus stays cautious
The latest brokerage activity in the same report included a target cut to $7.50 from $11.00 by Citigroup, plus a separate sell rating from Weiss Ratings. The result is a consensus rating of Hold and a consensus target of $7.54, which leaves the stock trading against a market view that is still cautious rather than optimistic.
That matters because the current setup mixes a revenue decline with a smaller-than-expected loss, so the next move in the shares will depend more on margin progress and guidance discipline than on top-line growth alone.
BetterHelp remains central
Teladoc Health's consumer unit BetterHelp remains the best-known product line in the company's portfolio, and it is still the business most retail investors associate with the brand. The unit's scale still makes it a reference point for any read-through on growth, retention, and profitability.
Teladoc Health shares last traded at $6.50, and the stock was up 2.20 percent in the market snapshot included with the search results. That leaves the shares well below the $7.54 consensus target and gives the latest earnings and guidance figures extra weight as the market looks at the next leg.
Fact box
Company: Teladoc Health, Inc.
ISIN: US87918A1051
Ticker: TDOC
Exchange: NYSE
Sector / Industry: Health Care / Health Care Technology
Price (as of August 30, 2026): $6.50 USD
Market cap: $1.1 billion (as of August 30, 2026)
